Overview

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

Status:
Unknown status
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range. Patients who require chronic anticoagulation with one or more of the following conditions are eligible for the study: atrial fibrillation or atrial flutter, prosthetic heart valve, venous thromboembolic disease, or history of myocardial infarction or cardiomyopathy will be enrolled.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
ARYx Therapeutics
Treatments:
Vitamin K
Vitamins
Warfarin